{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:50:15Z","timestamp":1787273415766,"version":"build-2736575974"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acromegaly is a rare and insidious disease characterized by chronic excess growth hormone, leading to various morphological changes and systemic complications. Despite its low prevalence, acromegaly poses a significant socioeconomic burden on patients and healthcare systems. This review synthesizes the current state of knowledge on the psychosocial burden, disability, impact on daily life, and cost of acromegaly disease, focusing on the quality of life, partnership, medical care and treatment afflictions, participation in daily activities, professional and leisure impairment, and cost of treatment for acromegaly and its comorbidities. It also examines management strategies, coping mechanisms, and interventions aimed at alleviating this burden. A comprehensive understanding of the extent of the socioeconomic burden in acromegaly is crucial to develop effective strategies to improve treatment and care. Further research is warranted to explore the myriad factors contributing to this burden, as well as the efficacy of interventions to alleviate it, ultimately enhancing the quality of life for patients with acromegaly.<\/jats:p>","DOI":"10.1093\/ejendo\/lvad097","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T22:09:50Z","timestamp":1691100590000},"page":"R1-R10","source":"Crossref","is-referenced-by-count":17,"title":["The socioeconomic burden of acromegaly"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5465-3491","authenticated-orcid":false,"given":"Sylv\u00e8re","family":"St\u00f6rmann","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , 80336 Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-0030","authenticated-orcid":false,"given":"Thomas","family":"Cuny","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Aix Marseille University, MMG, INSERM U1251, MarMaRa Institute, CRMR HYPO , Marseille 13385 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"issue":"1","key":"2023081109203323000_lvad097-B1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev."},{"issue":"2","key":"2023081109203323000_lvad097-B2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/EJE-21-0216","article-title":"Global epidemiology of acromegaly: a systematic review and meta-analysis","volume":"185","author":"Crisafulli","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023081109203323000_lvad097-B3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/cen.14828","article-title":"The prevalence of acromegaly is higher than previously reported: changes over a three-decade period","volume":"97","author":"Aagaard","year":"2022","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2023081109203323000_lvad097-B4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2017","journal-title":"Pituitary"},{"issue":"1","key":"2023081109203323000_lvad097-B5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"2023081109203323000_lvad097-B6","doi-asserted-by":"crossref","first-page":"848","DOI":"10.21037\/atm-22-3653","article-title":"Let's focus more on regional diversity of acromegaly","volume":"10","author":"St\u00f6rmann","year":"2022","journal-title":"Ann Transl Med."},{"issue":"7","key":"2023081109203323000_lvad097-B7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1530\/EC-21-0035","article-title":"Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers","volume":"10","author":"Varlamov E","year":"2021","journal-title":"Endocr Connect."},{"issue":"2","key":"2023081109203323000_lvad097-B8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","article-title":"Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed","volume":"72","author":"Reid","year":"2010","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2023081109203323000_lvad097-B9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023081109203323000_lvad097-B10","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1007\/s00701-021-04846-8","article-title":"Prevalence and outcome of comorbidities associated with acromegaly","volume":"163","author":"Berkmann","year":"2021","journal-title":"Acta Neurochir (Wien)"},{"issue":"7","key":"2023081109203323000_lvad097-B11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","article-title":"Socio-economic burden of rare diseases: a systematic review of cost of illness evidence","volume":"119","author":"Angelis","year":"2015","journal-title":"Health Policy"},{"issue":"1","key":"2023081109203323000_lvad097-B12","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab176","article-title":"Racial disparities in acromegaly and Cushing's disease: a referral center study in 241 patients","volume":"6","author":"Ioachimescu","year":"2022","journal-title":"J Endocr Soc"},{"issue":"10","key":"2023081109203323000_lvad097-B13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40618-022-01782-x","article-title":"Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management","volume":"45","author":"Camerini","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2023081109203323000_lvad097-B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-2-13","article-title":"Acromegaly quality of life questionnaire (AcroQoL)","volume":"2","author":"Badia","year":"2004","journal-title":"Health Qual Life Outcomes."},{"issue":"2","key":"2023081109203323000_lvad097-B15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.1.02214","article-title":"Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study","volume":"155","author":"Webb","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023081109203323000_lvad097-B16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11102-019-00986-4","article-title":"Development of a novel patient-reported measure for acromegaly: the acro-TSQ","volume":"22","author":"Fleseriu","year":"2019","journal-title":"Pituitary"},{"issue":"5","key":"2023081109203323000_lvad097-B17","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023081109203323000_lvad097-B18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s11102-015-0702-1","article-title":"Diagnosis and management of acromegaly: the patient's perspective","volume":"19","author":"Kreitschmann-Andermahr","year":"2016","journal-title":"Pituitary"},{"issue":"3-4","key":"2023081109203323000_lvad097-B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000095521","article-title":"The cost of medical care for the acromegalic patient","volume":"83","author":"Knutzen","year":"2006","journal-title":"Neuroendocrinology"},{"issue":"7","key":"2023081109203323000_lvad097-B20","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3390\/jcm10071363","article-title":"Towards an earlier diagnosis of acromegaly and gigantism","volume":"10","author":"Sisco","year":"2021","journal-title":"J Clin Med."},{"issue":"3","key":"2023081109203323000_lvad097-B21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-21-1071","article-title":"Virtual education programming for patients with acromegaly: a pilot study","volume":"186","author":"Geer","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023081109203323000_lvad097-B22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/EJE-19-0732","article-title":"The effect of treatment on quality of life in patients with acromegaly: a prospective study","volume":"182","author":"Wolters","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023081109203323000_lvad097-B23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2265.2007.03169.x","article-title":"Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly","volume":"69","author":"van der Klaauw","year":"2008","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2023081109203323000_lvad097-B24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/cen.13331","article-title":"Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study","volume":"86","author":"Kyriakakis","year":"2017","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2023081109203323000_lvad097-B25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s11102-021-01153-4","article-title":"Surgically treated acromegaly patients have a similar quality of life whether controlled by surgery or requiring additional medical therapy (QuaLAT study)","volume":"24","author":"Arshad","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"2023081109203323000_lvad097-B26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12020-014-0166-5","article-title":"Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases?","volume":"47","author":"Anagnostis","year":"2014","journal-title":"Endocrine"},{"issue":"1","key":"2023081109203323000_lvad097-B27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1210\/clinem\/dgaa750","article-title":"Quality of life and its determinants in patients with treated acromegaly: a cross-sectional nationwide study in China","volume":"106","author":"Guo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023081109203323000_lvad097-B28","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1210\/jc.2004-0669","article-title":"Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess","volume":"89","author":"Biermasz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023081109203323000_lvad097-B29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11102-022-01224-0","article-title":"Quality of life after long-term biochemical control of acromegaly","volume":"25","author":"Kimball","year":"2022","journal-title":"Pituitary"},{"issue":"10","key":"2023081109203323000_lvad097-B30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jfma.2018.12.017","article-title":"A registry of acromegaly patients and one year following up in Taiwan","volume":"118","author":"Tseng","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"2023081109203323000_lvad097-B31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4158\/EP161373.OR","article-title":"Predictors of quality of life in 165 patients with acromegaly: results from a single-center study","volume":"23","author":"Kreitschmann-Andermahr","year":"2017","journal-title":"Endocr Pract."},{"key":"2023081109203323000_lvad097-B32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fendo.2014.00229","article-title":"Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life","volume":"5","author":"Geraedts","year":"2015","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2023081109203323000_lvad097-B33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11102-014-0561-1","article-title":"Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL","volume":"18","author":"Andela","year":"2015","journal-title":"Pituitary"},{"key":"2023081109203323000_lvad097-B34","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3389\/fendo.2019.00899","article-title":"Importance of illness acceptance among other factors affecting quality of life in acromegaly","volume":"10","author":"Jawiarczyk-Przyby\u0142owska","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"2023081109203323000_lvad097-B35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1210\/clinem\/dgaa868","article-title":"Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis","volume":"106","author":"Broersen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023081109203323000_lvad097-B36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/014107680109401103","article-title":"Quality of life: impact of chronic illness on the partner","volume":"94","author":"Rees","year":"2001","journal-title":"J R Soc Med."},{"issue":"12","key":"2023081109203323000_lvad097-B37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1177\/1359105317695427","article-title":"The partner's perspective of the impact of pituitary disease: looking beyond the patient","volume":"24","author":"Andela","year":"2019","journal-title":"J Health Psychol."},{"issue":"6","key":"2023081109203323000_lvad097-B38","doi-asserted-by":"crossref","first-page":"K19","DOI":"10.1530\/EJE-21-0537","article-title":"Acromegaly in remission: a view from the partner","volume":"185","author":"Fourneaux","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2023081109203323000_lvad097-B39","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/BF03345805","article-title":"Growth hormone, prolactin, and sexuality","volume":"35","author":"Galdiero","year":"2012","journal-title":"J Endocrinol Invest."},{"key":"2023081109203323000_lvad097-B40","first-page":"562","article-title":"Erectile dysfunction is associated with excessive growth hormone levels in male patients with acromegaly","volume":"12","author":"Chen","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2023081109203323000_lvad097-B41","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11154-022-09721-0","article-title":"Acromegaly and male sexual health","volume":"23","author":"Salvio","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2023081109203323000_lvad097-B42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1530\/EJE-22-0263","article-title":"Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study","volume":"187","author":"Pivonello","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023081109203323000_lvad097-B43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1507\/endocrj.EJ12-0424","article-title":"Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center","volume":"60","author":"Celik","year":"2013","journal-title":"Endocr J."},{"issue":"1","key":"2023081109203323000_lvad097-B44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1517\/14728214.2014.875529","article-title":"Emerging drugs for acromegaly","volume":"19","author":"St\u00f6rmann","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"2023081109203323000_lvad097-B45","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1210\/jc.2016-1257","article-title":"Reference values for IGF-I serum concentrations: comparison of six immunoassays","volume":"101","author":"Chanson","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023081109203323000_lvad097-B46","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac081","article-title":"Differences in the distribution of IGF-I concentrations between European and US populations","volume":"6","author":"Bidlingmaier","year":"2022","journal-title":"J Endocr Soc"},{"key":"2023081109203323000_lvad097-B47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2017.00040","article-title":"Predictors of quality of life in acromegaly: no consensus on biochemical parameters","volume":"8","author":"Geraedts","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2023081109203323000_lvad097-B48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11102-022-01206-2","article-title":"Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience","volume":"25","author":"Salvatori","year":"2022","journal-title":"Pituitary"},{"issue":"10","key":"2023081109203323000_lvad097-B49","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023081109203323000_lvad097-B50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/cen.14309","article-title":"Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly","volume":"94","author":"Dichtel","year":"2021","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2023081109203323000_lvad097-B51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ghir.2015.06.008","article-title":"More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life","volume":"25","author":"Andela","year":"2015","journal-title":"Growth Horm IGF Res"},{"issue":"3","key":"2023081109203323000_lvad097-B52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023081109203323000_lvad097-B53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s11102-021-01163-2","article-title":"Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results","volume":"24","author":"Labadzhyan","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"2023081109203323000_lvad097-B54","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"1","key":"2023081109203323000_lvad097-B55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev."},{"issue":"2","key":"2023081109203323000_lvad097-B56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12020-012-9781-1","article-title":"Acromegalic arthropathy: current perspectives","volume":"43","author":"Romijn","year":"2013","journal-title":"Endocrine"},{"issue":"3","key":"2023081109203323000_lvad097-B57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1530\/EJE-08-0845","article-title":"High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case\u2013control study","volume":"160","author":"Wassenaar","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023081109203323000_lvad097-B58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11102-013-0464-6","article-title":"Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study","volume":"17","author":"Claessen","year":"2014","journal-title":"Pituitary"},{"issue":"2","key":"2023081109203323000_lvad097-B59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1530\/EJE-12-0147","article-title":"Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study","volume":"167","author":"Claessen","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023081109203323000_lvad097-B60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1210\/clinem\/dgaa747","article-title":"Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up","volume":"106","author":"Pelsma","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023081109203323000_lvad097-B61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ecl.2022.04.004","article-title":"Evaluating the impact of acromegaly on quality of life","volume":"51","author":"Coopmans","year":"2022","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"6","key":"2023081109203323000_lvad097-B62","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1586\/14737167.2014.963559","article-title":"Health-related quality of life in primary and secondary adrenal insufficiency","volume":"14","author":"Aulinas","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"1","key":"2023081109203323000_lvad097-B63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023081109203323000_lvad097-B64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023081109203323000_lvad097-B65","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-18-0015","article-title":"Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study","volume":"178","author":"Esposito","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023081109203323000_lvad097-B66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023081109203323000_lvad097-B67","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CRD.0000000000000215","article-title":"Acromegalic cardiomyopathy: an overview of risk factors, clinical manifestations, and therapeutic options","volume":"26","author":"Goldberg","year":"2018","journal-title":"Cardiol Rev"},{"issue":"22","key":"2023081109203323000_lvad097-B68","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-Related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"2023081109203323000_lvad097-B69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12020-013-0106-9","article-title":"Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study","volume":"46","author":"Yedinak","year":"2014","journal-title":"Endocrine"},{"issue":"6","key":"2023081109203323000_lvad097-B70","first-page":"255","article-title":"Cognitive impairment and psychopathology in patients with pituitary diseases","volume":"70","author":"Pereira","year":"2012","journal-title":"Neth J Med."},{"issue":"1","key":"2023081109203323000_lvad097-B71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.17219\/acem\/38156","article-title":"The quality of life and psychological, social and cognitive functioning of patients with acromegaly","volume":"24","author":"Szcze\u015bniak","year":"2015","journal-title":"Adv Clin Exp Med."},{"issue":"12","key":"2023081109203323000_lvad097-B72","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2362.2012.02721.x","article-title":"Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition","volume":"42","author":"Brummelman","year":"2012","journal-title":"Eur J Clin Invest."},{"issue":"3","key":"2023081109203323000_lvad097-B73","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11102-011-0326-z","article-title":"Cognitive function in acromegaly: description and brain volumetric correlates","volume":"15","author":"Sievers","year":"2012","journal-title":"Pituitary"},{"issue":"4","key":"2023081109203323000_lvad097-B74","doi-asserted-by":"crossref","first-page":"e60041","DOI":"10.1371\/journal.pone.0060041","article-title":"Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus na\u00efve acromegaly","volume":"8","author":"Mart\u00edn-Rodr\u00edguez","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"2023081109203323000_lvad097-B75","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/jcm12062283","article-title":"Cognitive dysfunction, an increasingly valued long-term impairment in acromegaly","volume":"12","author":"Chen","year":"2023","journal-title":"J Clin Med."},{"issue":"3","key":"2023081109203323000_lvad097-B76","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11102-008-0143-1","article-title":"Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study","volume":"12","author":"Sievers","year":"2009","journal-title":"Pituitary"},{"issue":"4","key":"2023081109203323000_lvad097-B77","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10143-019-01134-z","article-title":"Pituitary adenomas and neuropsychological status: a systematic literature review","volume":"43","author":"Pertichetti","year":"2020","journal-title":"Neurosurg Rev."},{"issue":"1-3","key":"2023081109203323000_lvad097-B78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12020-008-9112-8","article-title":"Psychosocial morbidity in acromegaly: a study from India","volume":"34","author":"Mattoo","year":"2008","journal-title":"Endocrine"},{"issue":"3","key":"2023081109203323000_lvad097-B79","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EJE-08-0896","article-title":"Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls","volume":"160","author":"Sievers","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2023081109203323000_lvad097-B80","article-title":"Economic burden of disease of uncontrolled acromegalic patients: the acromegaly Italian collaborative study group","author":"Mennini","year":"2018","journal-title":"Glob Reg Health Technol Assess"},{"issue":"6","key":"2023081109203323000_lvad097-B81","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11102-018-0913-3","article-title":"Work disability and its determinants in patients with pituitary tumor-related disease","volume":"21","author":"Lobatto","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"2023081109203323000_lvad097-B82","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ando.2018.08.006","article-title":"Daily life, needs and expectations of patients with acromegaly in France: an on-line survey","volume":"80","author":"Albarel","year":"2019","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"2023081109203323000_lvad097-B83","first-page":"320","article-title":"ACROSTART: a retrospective study of the time to achieve hormonal control with lanreotide autogel treatment in Spanish patients with acromegaly","volume":"66","author":"\u00c1lvarez-Escol\u00e1","year":"2019","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"1","key":"2023081109203323000_lvad097-B84","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/13696998.2021.1898968","article-title":"Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care","volume":"24","author":"Ribeiro-Oliveira","year":"2021","journal-title":"J Med Econ"},{"issue":"10","key":"2023081109203323000_lvad097-B85","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eprac.2021.04.412","article-title":"Health benefit costs and absenteeism among employed patients with acromegaly","volume":"27","author":"Yuen","year":"2021","journal-title":"Endocr Pract."},{"issue":"3","key":"2023081109203323000_lvad097-B86","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/jim-2017-000570","article-title":"Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly","volume":"66","author":"Liu","year":"2018","journal-title":"J Investig Med."},{"issue":"9","key":"2023081109203323000_lvad097-B87","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1210\/clinem\/dgaa405","article-title":"Disease control and gender predict the socioeconomic effects of acromegaly: a nationwide cohort study","volume":"105","author":"Dal","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2023081109203323000_lvad097-B88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"2023081109203323000_lvad097-B89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","article-title":"An evaluation of the acromegaly treatment satisfaction questionnaire (acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies","volume":"23","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"issue":"2","key":"2023081109203323000_lvad097-B90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-16-0623","article-title":"Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study","volume":"176","author":"Les\u00e9n","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023081109203323000_lvad097-B91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s11102-018-0908-0","article-title":"Cost-effectiveness of acromegaly treatments: a systematic review","volume":"21","author":"Leonart","year":"2018","journal-title":"Pituitary"},{"issue":"3","key":"2023081109203323000_lvad097-B92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40801-015-0039-0","article-title":"Treatment patterns and economic burden in patients treated for acromegaly in the USA","volume":"2","author":"Chuang","year":"2015","journal-title":"Drugs Real World Outcomes"},{"issue":"4","key":"2023081109203323000_lvad097-B93","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11102-013-0506-0","article-title":"Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases","volume":"17","author":"Broder","year":"2014","journal-title":"Pituitary"},{"issue":"12","key":"2023081109203323000_lvad097-B94","first-page":"1106","article-title":"Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis","volume":"21","author":"Placzek","year":"2015","journal-title":"J Manag Care Spec Pharm."},{"issue":"3","key":"2023081109203323000_lvad097-B95","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3171\/2012.4.JNS11739","article-title":"Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly","volume":"117","author":"Marko","year":"2012","journal-title":"J Neurosurg."},{"key":"2023081109203323000_lvad097-B96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2021.101389","article-title":"Economic and clinical burden of comorbidities among patients with acromegaly","volume":"59","author":"Whittington","year":"2021","journal-title":"Growth Horm IGF Res."},{"issue":"1","key":"2023081109203323000_lvad097-B97","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11102-016-0765-7","article-title":"The surgical treatment of acromegaly","volume":"20","author":"Buchfelder","year":"2017","journal-title":"Pituitary"},{"key":"2023081109203323000_lvad097-B98","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.905019","article-title":"Costs and its determinants in pituitary tumour surgery","volume":"13","author":"Dekkers","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"2023081109203323000_lvad097-B99","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1530\/EJE-07-0366","article-title":"Optimalization and cost management of lanreotide-autogel therapy in acromegaly","volume":"157","author":"Abrams","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023081109203323000_lvad097-B100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0030-1267244","article-title":"Efficacy and acceptability of lanreotide autogel \u00ae 120\u2005mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR","volume":"119","author":"Schopohl","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"1","key":"2023081109203323000_lvad097-B101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11102-022-01285-1","article-title":"A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly","volume":"26","author":"Fleseriu","year":"2023","journal-title":"Pituitary"},{"issue":"1","key":"2023081109203323000_lvad097-B102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14737167.2018.1513330","article-title":"Cost-effectiveness of somatostatin analogues in the treatment of acromegaly","volume":"19","author":"Orlewska","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"4","key":"2023081109203323000_lvad097-B103","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3111\/13696998.2015.1127816","article-title":"Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder","volume":"19","author":"Zhang","year":"2016","journal-title":"J Med Econ."},{"issue":"1","key":"2023081109203323000_lvad097-B104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737167.2019.1610396","article-title":"Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain","volume":"20","author":"Peral","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2023081109203323000_lvad097-B105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2021.745843","article-title":"Cost-Utility of acromegaly pharmacological treatments in a French context","volume":"12","author":"Brue","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"2023081109203323000_lvad097-B106","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000507890","article-title":"Pharmacological acromegaly treatment: cost-utility and value of information analysis","volume":"111","author":"Leonart","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"2","key":"2023081109203323000_lvad097-B107","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11102-021-01193-w","article-title":"Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length","volume":"25","author":"Cocchiara","year":"2022","journal-title":"Pituitary"},{"issue":"7","key":"2023081109203323000_lvad097-B108","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s40618-015-0242-6","article-title":"Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases","volume":"38","author":"Duan","year":"2015","journal-title":"J Endocrinol Invest."},{"issue":"9","key":"2023081109203323000_lvad097-B109","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ejim.2015.07.019","article-title":"Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome","volume":"26","author":"Margusino-Frami\u00f1\u00e1n","year":"2015","journal-title":"Eur J Intern Med."},{"issue":"9","key":"2023081109203323000_lvad097-B110","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023081109203323000_lvad097-B111","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1210\/jc.2010-2490","article-title":"Coping strategies in patients after treatment for functioning or nonfunctioning pituitary adenomas","volume":"96","author":"Tiemensma","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023081109203323000_lvad097-B112","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1210\/jc.2011-1645","article-title":"Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly","volume":"96","author":"Tiemensma","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023081109203323000_lvad097-B113","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11102-012-0432-6","article-title":"Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases","volume":"16","author":"Burton","year":"2013","journal-title":"Pituitary"},{"issue":"7","key":"2023081109203323000_lvad097-B114","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2011-0237","article-title":"A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification","volume":"96","author":"Schneider","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023081109203323000_lvad097-B115","doi-asserted-by":"crossref","first-page":"M39","DOI":"10.1530\/EJE-15-0429","article-title":"Diagnostic use of facial image analysis software in endocrine and genetic disorders: review, current results and future perspectives","volume":"173","author":"Kosilek","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2023081109203323000_lvad097-B116","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ebiom.2017.12.015","article-title":"Automatic detection of acromegaly from facial photographs using machine learning methods","volume":"27","author":"Kong","year":"2018","journal-title":"EBioMedicine"},{"issue":"8","key":"2023081109203323000_lvad097-B117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1590\/0004-2730000003314","article-title":"Screening for acromegaly in adult patients not reporting enlargement of the extremities, but with arterial hypertension associated with another comorbidity of the disease","volume":"58","author":"Rosario","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"1","key":"2023081109203323000_lvad097-B118","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12020-018-1618-0","article-title":"Screening of acromegaly in adults with obstructive sleep apnea: is it worthwhile?","volume":"61","author":"Attal","year":"2018","journal-title":"Endocrine"},{"issue":"7","key":"2023081109203323000_lvad097-B119","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1055\/s-0042-100913","article-title":"Screening for acromegaly in patients with carpal tunnel syndrome: a prospective study (ACROCARP)","volume":"48","author":"Zoicas","year":"2016","journal-title":"Horm Metab Res"},{"issue":"2","key":"2023081109203323000_lvad097-B120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12020-018-1538-z","article-title":"IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea","volume":"60","author":"Heinrich","year":"2018","journal-title":"Endocrine"},{"issue":"4","key":"2023081109203323000_lvad097-B121","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11102-016-0714-5","article-title":"Implementing a screening program for acromegaly in Latin America: necessity versus feasibility","volume":"19","author":"Danilowicz","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"2023081109203323000_lvad097-B122","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4158\/EP161575.OR","article-title":"An approach to using data mining to support early identification of acromegaly","volume":"23","author":"Broder","year":"2017","journal-title":"Endocr Pract."},{"issue":"5","key":"2023081109203323000_lvad097-B123","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1227\/NEU.0b013e31826d5d06","article-title":"Pituitary centers of excellence","volume":"71","author":"McLaughlin","year":"2012","journal-title":"Neurosurgery"},{"issue":"1","key":"2023081109203323000_lvad097-B124","doi-asserted-by":"crossref","first-page":"E143","DOI":"10.1227\/NEU.0000000000000153","article-title":"Pituitary centers of excellence: for patients it is life or death","volume":"74","author":"Knutzen","year":"2014","journal-title":"Neurosurgery"},{"issue":"5","key":"2023081109203323000_lvad097-B125","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"key":"2023081109203323000_lvad097-B126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2019.00380","article-title":"The effect of cognitive-behavioral therapy on acromegalics after a 9-month follow-up","volume":"10","author":"Kunzler","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"6","key":"2023081109203323000_lvad097-B127","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1530\/EJE-20-0652","article-title":"Evaluation of an individualized education program in pituitary diseases: a pilot study","volume":"183","author":"Albarel","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023081109203323000_lvad097-B128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14844","article-title":"The effect of mindfulness therapy in acromegaly, a pilot study","volume":"98","author":"Santos","year":"2023","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad097\/51034925\/lvad097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/189\/2\/R1\/51096397\/lvad097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/189\/2\/R1\/51096397\/lvad097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T09:21:51Z","timestamp":1691745711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/189\/2\/R1\/7236762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":128,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad097","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,8]]}}}